Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alaunos Therapeutics, Inc. TCRT

Healthcare  —  Biotechnology
1.09 (0.04) (3.54%) as of 25 Sep
Market cap
$2.9M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Alaunos Therapeutics, Inc. (TCRT) Business Profile

Updated before January 2025

Company Overview

Alaunos Therapeutics, Inc. (NASDAQ: TCRT) is a clinical-stage biotechnology company focused on developing innovative cell therapy solutions for the treatment of cancer. Originally founded in 2011 under the name ZIOPHARM Oncology, the company rebranded to Alaunos Therapeutics in 2021 to better reflect its strategic focus on advancing T-cell receptor (TCR) therapies. Headquartered in Houston, Texas, Alaunos leverages its proprietary TCR-T cell platform to target solid tumors, aiming to address unmet medical needs in oncology.

The company is led by a team of seasoned professionals with extensive experience in biotechnology and oncology. Kevin S. Boyle, Sr., serves as the Chief Executive Officer, bringing a wealth of expertise in corporate strategy and operational leadership. Other key members of the leadership team include Drew Deniger, Ph.D., Senior Vice President of Research and Development, and Carsten Reinhardt, M.D., Ph.D., Chief Medical Officer. Together, they drive Alaunos’ mission to transform the lives of cancer patients through groundbreaking therapies.

Core Business Segments

Alaunos Therapeutics operates primarily in the field of cell therapy, with a focus on TCR-T cell therapies. Its core business segments include:

TCR-T Cell Therapy

Alaunos’ flagship offering is its TCR-T cell therapy platform, which utilizes non-viral Sleeping Beauty technology to engineer T cells to target specific tumor antigens. This approach is designed to enhance the efficacy and safety of cancer treatments. Key features of this platform include:

  • Sleeping Beauty Technology: A non-viral gene transfer system that enables rapid and cost-effective manufacturing of TCR-T cells.
  • Library of TCRs: A proprietary library of T-cell receptors targeting shared tumor antigens, allowing for personalized treatment options.
  • Focus on Solid Tumors: Unlike many cell therapies that target hematologic malignancies, Alaunos is pioneering treatments for solid tumors, which represent a significant unmet need in oncology.

Clinical Trials and Pipeline

Alaunos is actively conducting clinical trials to evaluate the safety and efficacy of its TCR-T therapies. Its lead program targets KRAS, a common mutation in solid tumors, and is currently in Phase 1/2 trials. The company’s pipeline also includes additional TCR candidates targeting other tumor antigens.

Business Model

Alaunos Therapeutics operates on a research-driven business model, integrating cutting-edge science with a patient-centric approach. The company generates revenue primarily through:

  • Collaborations and Partnerships: Alaunos collaborates with academic institutions, research organizations, and industry partners to advance its technology and expand its pipeline.
  • Licensing Agreements: The company licenses its proprietary technologies, such as the Sleeping Beauty platform, to other biotech firms, generating additional revenue streams.
  • Clinical Development: While still in the clinical stage, Alaunos aims to commercialize its therapies upon regulatory approval, creating long-term revenue opportunities.

Strategic Direction

Alaunos Therapeutics is committed to advancing its TCR-T cell therapy platform and expanding its pipeline to address a broader range of cancers. Key strategic priorities include:

  • Pipeline Expansion: Developing additional TCR candidates targeting new tumor antigens and mutations.
  • Manufacturing Innovation: Enhancing its manufacturing capabilities to support scalable and cost-effective production of TCR-T cells.
  • Regulatory Milestones: Achieving key regulatory approvals to bring its therapies to market.
  • Sustainability Goals: Implementing environmentally sustainable practices in its research and manufacturing processes.

Competitive Landscape

Alaunos Therapeutics operates in a highly competitive biotechnology sector, facing competition from both established players and emerging startups. Key competitors include:

  • Adaptimmune Therapeutics: A leader in TCR therapies with a focus on solid tumors.
  • Kite Pharma (a Gilead Company): Known for its CAR-T cell therapies, Kite is expanding into TCR-based approaches.
  • Immunocore: Specializes in TCR-based therapies for cancer and infectious diseases.
  • Bluebird Bio: Focuses on gene and cell therapies, including TCR technologies.

Despite the competition, Alaunos differentiates itself through its proprietary Sleeping Beauty platform and focus on solid tumors, which remain a challenging area in oncology.

Risk Factors

Like any clinical-stage biotech company, Alaunos Therapeutics faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s ability to commercialize its therapies.
  • Market Dependence: As a clinical-stage company, Alaunos is heavily reliant on external funding and partnerships to sustain its operations.
  • Supply Chain Challenges: Disruptions in the supply chain for raw materials and manufacturing components could delay clinical trials and product development.
  • Competitive Pressure: The rapidly evolving biotech landscape poses a constant threat from competitors with similar or superior technologies.

Recent Developments

Alaunos has made significant progress in advancing its TCR-T cell therapy platform. Recent developments include:

  • Clinical Trial Updates: Positive interim data from its Phase 1/2 trial targeting KRAS mutations, demonstrating safety and early signs of efficacy.
  • Partnerships: Collaboration with leading academic institutions to expand its TCR library and explore new therapeutic targets.
  • Manufacturing Enhancements: Investment in state-of-the-art manufacturing facilities to support the production of TCR-T cells at scale.

Global developments, such as the COVID-19 pandemic, have also influenced Alaunos’ operations, highlighting the importance of robust supply chain management and adaptive clinical trial strategies.

Investment Considerations

Investors considering Alaunos Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Proprietary Sleeping Beauty platform offers a competitive edge in TCR-T cell therapy.
  • Focus on Solid Tumors: Addresses a significant unmet need in oncology.
  • Experienced Leadership: Strong management team with expertise in biotechnology and oncology.

Risks

  • Clinical-Stage Status: Lack of commercialized products means the company is not yet generating significant revenue.
  • Regulatory Uncertainty: Success depends on achieving key regulatory milestones.
  • Market Volatility: The biotech sector is inherently volatile, with stock prices influenced by trial results and market sentiment.

Conclusion

Alaunos Therapeutics, Inc. is at the forefront of innovation in TCR-T cell therapy, leveraging its proprietary technology to address unmet needs in cancer treatment. While the company faces challenges typical of clinical-stage biotechs, its focus on solid tumors and commitment to advancing its pipeline position it as a promising player in the oncology space. With a clear strategic direction and a strong leadership team, Alaunos is well-positioned for future growth and success in the competitive biotech landscape.